Genocea to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January. Conferences: Event:Longwood Healthcare Leaders Winter Webconference – DetailsTopic 1:Innovation in Cell TherapyFormat:PanelDate:Thursday, January 6, 2022Time:1:30 PM ETTopic 2:Making a Big Impact With Limited ResourcesFormat:Date:Time:PanelThursday, January 6, 20225:10 PM ETEvent:LifeSci Partners 11th Annual Corporate Access Event – DetailsTopic 1:Innovative Approaches to Cell Therapy for OncologyFormat:PanelDate:Friday, January 7, 2022Time:8:30 AM ETTopic 2:Cancer Vaccines: Promises, Promises … Has Their Day Come?Format:Date:Time:PanelFriday, January 7, 20222:00 PM ET Event:H.C. Wainwright BIOCONNECT Virtual Conference – DetailsTopic:Corporate UpdateFormat:On demand presentationDate:Monday, January 10, 2022Time:7:00 AM ET Event:Advanced Therapies Week – DetailsTopic:Add It Up: 3 Things to Consider for Capacity ExpansionFormat:PanelDate:Wednesday, January 26, 2022Time:5:00 PM ET About Genocea Biosciences, Inc.Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. We have two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy comprising neoantigen-targeted peripheral cells for which we are conducting a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com. Investor Contact:  Media Contact:Dan Ferry  Sarah O’Connell617-430-7576  [email protected] [email protected]